How should a reproductive‑age woman with menorrhagia be evaluated and managed?

Evaluation and Management of Menorrhagia in Reproductive-Age Women

A reproductive-age woman with menorrhagia should first undergo pelvic examination and transvaginal ultrasound to identify structural causes (fibroids, polyps, adenomyosis), followed by endometrial sampling if she is >45 years old or has risk factors for endometrial cancer, with first-line medical treatment being the levonorgestrel-releasing intrauterine system (LNG-IUS), tranexamic acid, or NSAIDs before considering surgical intervention.

Initial Evaluation

Clinical Assessment

• Quantify bleeding severity: Assess for anemia through hemoglobin/hematocrit levels 1
• Rule out pregnancy as the first step in any woman of reproductive age with abnormal bleeding 2
• Assess bleeding pattern: Heavy menstrual bleeding is defined as cyclic bleeding that is heavy or prolonged 3
• Screen for coagulopathies: Consider underlying bleeding disorders, especially in women with menorrhagia since menarche 4, 5

Diagnostic Workup

Imaging is essential for identifying structural causes:

• Transvaginal ultrasound is the primary imaging modality 2, 6
• Saline infusion sonohysterography has 96-100% sensitivity for detecting intracavitary lesions (polyps, submucosal fibroids) and provides superior endometrial assessment 7
• MRI should be considered when ultrasound cannot adequately visualize the endometrium due to fibroids or adenomyosis 2

Endometrial sampling indications 2, 7:

• Age >45 years
• Failed medical management
• Risk factors for endometrial cancer (obesity, PCOS, unopposed estrogen exposure)
• Endometrial thickness concerns on imaging

Common Structural Causes by Age

• Under 40 years: Fibroids are most common 6
• Over 40 years: Endometrial polyps predominate 6
• Any age: Adenomyosis should be considered 8

Medical Management (First-Line Treatment)

Medical therapy should be initiated before considering surgical options 6, 9. The hierarchy of effectiveness:

Most Effective: Levonorgestrel-Releasing Intrauterine System (LNG-IUS)

• Reduces menstrual blood loss by 71-95% 3
• Efficacy comparable to endometrial ablation or hysterectomy 6
• Particularly effective for adenomyosis-related menorrhagia 10
• Can be used even in women with severe thrombocytopenia 11
• This is the single most effective medical treatment available 5

Highly Effective: Tranexamic Acid

• Reduces menstrual blood loss by 40-60% 6
• Non-hormonal option for women who cannot use hormonal therapy 6
• Caution: Should be avoided in women with cardiovascular disease or thrombotic risk 3

Effective: NSAIDs

• Reduce menstrual blood loss by 20-50% 6
• Mefenamic acid 500mg three times daily for 5-7 days during bleeding 12
• Can be used for short-term treatment (5-7 days) 12

Moderately Effective: Combined Oral Contraceptives

• Particularly effective for women with small fibroids 13
• Provides concurrent contraception 7
• Can be used for 10-20 days for acute bleeding management 12

Less Effective: Cyclic Progestogens

• Do NOT significantly reduce menstrual bleeding in ovulating women 6
• Should not be used as first-line therapy for idiopathic menorrhagia

Temporary Use: GnRH Agonists

• Reduce uterine and fibroid volume 13
• Major limitation: Symptoms recur after discontinuation, and chronic use causes bone loss 13
• Best reserved for preoperative fibroid shrinkage 13

Surgical Management (Second-Line Treatment)

Surgery should only be considered after medical management fails 6, 8.

For Women Desiring Future Pregnancy

• Hysteroscopic polypectomy for endometrial polyps 8
• Hysteroscopic myomectomy for submucosal fibroids 8
• Laparoscopic or abdominal myomectomy for intramural fibroids 8
• Recurrence rates after myomectomy: 23-33% 13

For Women Not Desiring Future Pregnancy

• Endometrial ablation: Effective but has 36% reintervention rate for fibroids >5cm 13
• Uterine artery embolization (UAE): Shorter hospital stay and recovery than hysterectomy, but higher reintervention rates 13
• Hysterectomy: Most definitive treatment with best long-term quality of life outcomes 13

Management Algorithm

1. Exclude pregnancy and assess hemodynamic stability 14
2. Perform pelvic examination and transvaginal ultrasound 2, 6
3. Consider endometrial sampling if age >45 or risk factors present 2, 7
4. Initiate medical therapy:
   • First choice: LNG-IUS 6, 5
   • Alternatives: Tranexamic acid or NSAIDs 6
   • Combined oral contraceptives if contraception desired 7
5. Evaluate response at 3-4 weeks (hemoglobin should rise by 2 g/dL) 1
6. Continue iron supplementation for 3 months after anemia correction 1
7. If medical management fails: Consider hysteroscopy for direct visualization and treatment of focal lesions 7
8. Surgical intervention only after failed medical therapy 6, 8

Critical Pitfalls to Avoid

• Do not use cyclic progestogens as first-line therapy in ovulating women—they are ineffective 6
• Do not proceed directly to surgery without attempting medical management 6
• Do not use tranexamic acid in women with cardiovascular disease or thrombotic risk 3
• Do not rely on patient's subjective assessment of blood loss—it does not correlate with actual volume 6
• Do not forget iron supplementation—continue for 3 months after hemoglobin normalizes to replenish stores 1
• Do not skip endometrial sampling in women >45 years or with risk factors for endometrial cancer 2, 7

Special Populations

Women with Bleeding Disorders

• LNG-IUS is highly effective and often leads to amenorrhea 5
• Combination therapy with tranexamic acid and desmopressin (DDAVP) can be used 5
• Enhanced coordination between gynecology and hematology is essential 5

Women on Antiplatelet Therapy

• Reassess indication for ongoing antiplatelet therapy 3
• LNG-IUS (levonorgestrel 20 μg/day) is the most effective option (71-95% reduction in bleeding) 3
• Avoid NSAIDs and tranexamic acid due to thrombotic risk 3